MCID: LRY044
MIFTS: 59

Larynx Cancer malady

Categories: Rare diseases, Cancer diseases, Respiratory diseases, Oral diseases

Aliases & Classifications for Larynx Cancer

About this section

Aliases & Descriptions for Larynx Cancer:

Name: Larynx Cancer 11 13
Laryngeal Carcinoma 11 47 49 13
Laryngeal Cancer 47 26 49
Laryngeal Benign Neoplasm 11 13
Carcinoma of Larynx 11 67
Malignant Neoplasm of Larynx 67
 
Laryngeal Neoplasms 38
Laryngeal Neoplasm 67
Neoplasm of Larynx 11
Cancer of Larynx 11
Larynx Neoplasm 11
Laryngeal Tumor 11

Classifications:



Summaries for Larynx Cancer

About this section
Wikipedia:70 Laryngeal cancer, also known as cancer of the larynx or laryngeal carcinoma, are mostly squamous cell... more...

MalaCards based summary: Larynx Cancer, also known as laryngeal carcinoma, is related to supraglottic laryngeal cancer and laryngeal cancer, childhood. An important gene associated with Larynx Cancer is GSTT1 (Glutathione S-Transferase Theta 1), and among its related pathways are Acetaminophen Pathway (therapeutic doses), Pharmacokinetics and Naphthalene metabolism. Affiliated tissues include the larynx, lung and breast, and related mouse phenotypes are vision/eye and endocrine/exocrine gland.

Disease Ontology:11 A larynx cancer that has material basis in epithelial cells.

Related Diseases for Larynx Cancer

About this section

Diseases in the Larynx Cancer family:

Larynx Carcinoma in Situ

Diseases related to Larynx Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 164)
idRelated DiseaseScoreTop Affiliating Genes
1supraglottic laryngeal cancer12.0
2laryngeal cancer, childhood11.8
3laryngeal neuroendocrine tumor10.9
4laryngeal endocrine tumor10.9
5laryngeal mucoepidermoid carcinoma10.9
6laryngeal adenoid cystic carcinoma10.9
7laryngeal small cell carcinoma10.9
8larynx sarcoma10.8
9salivary gland adenoid cystic carcinoma10.7CDKN2A, TP53
10emery-dreifuss muscular dystrophy, dominant type10.6GSTM1, GSTT1, NAT2
11biliary papillomatosis10.6CDKN2A, TP53
12berylliosis10.6GSTM1, GSTP1, GSTT1
13karak syndrome10.6CDKN2A, PTEN
14skeletal tuberculosis10.6CCND1, CDKN2A
15cavernous hemangioma of colon10.5GSTM1, GSTT1, MMP2
16esophagus verrucous carcinoma10.5CDKN2A, PTEN, TP53
17extra-adrenal pheochromocytoma10.5CD44, PTEN, TP53
18bronchitis10.5CDKN2A, NME1
19split hand split foot malformation autosomal recessive10.5CDKN2A, MKI67, TP53
20leukoencephalopathy palmoplantar keratoderma10.5CCND1, CD44, CDKN2A
21stroma-dominant and stroma-poor composite ganglioneuroblastoma10.5CDKN2A, TP53, XRCC1
22pelvic muscle wasting10.5CDKN2A, PTEN, TP53
23volkmann contracture10.5CDKN2A, MMP2, NME1
24sialolithiasis10.5CDKN2A, MKI67, TP53
25active cochleovestibular meniere's disease10.5CCND1, CDKN2A
26bladder verrucous squamous cell carcinoma10.4CCND1, CDKN2A, TP53
27hypersplenism10.4CDKN2A, PTEN, TERT
28oligodendroglioma10.4CCND1, CDKN2A, TP53
29splenic abscess10.4GSTP1, PTEN, TP53
30acute myocardial infarction10.4CDKN2A, GSTM1, GSTT1, TP53
31gastrointestinal neuroendocrine tumor10.4CCND1, CDKN2A, TP53
32adenosquamous pancreas carcinoma10.4CD44, CDKN2A, EGFR
33histidine metabolism disease10.4CCND1, CDKN2A, TP53
34adenoid squamous cell carcinoma10.4CDKN2A, TP53
35bilateral retinoblastoma10.4CCND1, CDKN2A, TP53
36compartment syndrome10.4CD44, CDKN2A, PTEN, TP53
37desmoplastic infantile astrocytoma10.4CCND1, CDKN2A, MKI67
38pharynx cancer10.4CCND1, CDKN2A, TP53
39prostate cancer, hereditary, x-linked 110.4GSTP1, PTEN, TP53
40ascending colon cancer10.4CCND1, CDKN2A, TP53
41boylan dew greco syndrome10.4CCND1, CDKN2A, TERT
42learning disability10.4CDKN2A, MMP2, TP53
43pineal region meningioma10.4GSTM1, PTEN, TP53, XRCC1
44penis carcinoma in situ10.4CDKN2A, MMP2, TP53
45male reproductive organ benign neoplasm10.3CCND1, CDKN2A, TP53
46amelogenesis imperfecta local hypoplastic10.3CDKN2A, MKI67
47tumor predisposition syndrome10.3CDKN2A, PTEN, TP53
48herpes simplex10.3CDKN2A, EGFR, TP53
49non-congenital cyst of kidney10.3CDKN2A, EGFR, PTEN
50stenosis of lacrimal sac10.3CCND1, CDKN2A, TP53

Comorbidity relations with Larynx Cancer via Phenotypic Disease Network (PDN):


BronchitisDeficiency Anemia
Protein-Energy MalnutritionRespiratory Failure
Swallowing DisordersPharynx Cancer
Supraglottis Cancer

Graphical network of the top 20 diseases related to Larynx Cancer:



Diseases related to larynx cancer

Symptoms for Larynx Cancer

About this section

Drugs & Therapeutics for Larynx Cancer

About this section

Drugs for Larynx Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 384)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
AcetylcysteineapprovedPhase 4316616-91-112035
Synonyms:
(2R)-2-acetylamino-3-Sulfanylpropanoic acid
(R)-2-acetylamino-3-Mercaptopropanoic acid
(R)-Mercapturic acid
2-Acetylamino-3-mercapto-propionate
2-Acetylamino-3-mercapto-propionic acid
ACC
Acetadote
Acetilcisteina
Acetylcysteine
Acetylcysteinum
Fluimicil Infantil
Fluimucetin
Fluimucil
Flumucetin
 
Fluprowit
L-Acetylcysteine
L-alpha-acetamido-beta-Mercaptopropionic acid
Lysox
Mercapturic acid
Mucolysin
Mucomyst
N-ACETYL-L-cysteine
N-Acety-L-Cysteine
N-Acetyl-3-mercaptoalanine
N-Acetyl-L-(+)-cysteine
N-Acetylcysteine
N-acetylcysteine
NAC
Parvolex
Sodium 2-acetamido-3-mercaptopropionate
2
CisplatinapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1269015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
3
BleomycinapprovedPhase 4, Phase 315311056-06-75360373
Synonyms:
(betaR)-N(alpha)-{[6-amino-2-((1S)-3-amino-1-{[(2S)-2,3-diamino-3-oxopropyl]amino}-3-oxopropyl)-5-methylpyrimidin-4-yl]carbonyl}-beta-{2-O-[3-O-(aminocarbonyl)-alpha-D-mannopyranosyl]-alpha-L-gulopyranosyloxy}-N-[(1R,2S,3S)-5-({(1S,2R)-1-[({2-[4-({[3-(dimethylsulfonio)propyl]amino}carbonyl)-2,4'-bi-1,3-thiazol-2'-yl]ethyl}amino)carbonyl]-2-hydroxypropyl}amino)-3-hydroxy-4-methyl-5-oxopentan-2-yl]-L-histidinamide
11056-06-7
11116-31-7
1400-95-9
3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2R,3S,4S,5S,6S)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S,3R)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2R,3S,4S,5S,6S)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S,3R)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[3-[4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
37208-04-1
37293-16-6
37353-43-8
9041-93-4
9041-93-4 (sulfate (salt))
AC1L9UFF
AC1NSEJD
AC1NUTOQ
BLM
Blenoxane
Bleo
Bleocin
Bleogin
Bleomicin
Bleomicina
Bleomicina [INN-Spanish]
Bleomycin A(2)
Bleomycin A2
Bleomycin A2 & Bleomycin B2.
Bleomycin B(2)
Bleomycin B2
Bleomycin sulfate
Bleomycin sulphate
 
Bleomycine
Bleomycine [INN-French]
Bleomycins
Bleomycinum
Bleomycinum [INN-Latin]
C06854
C55H85N17O21S3
C55H86N17O21S3
CCRIS 2754
CHEBI:3139
CHEMBL403664
CID456190
CID5360373
CID5460769
DB00290
EINECS 234-356-5
HSDB 3208
LMPK14000006
LS-44860
LS-524
N(1)-[3-(dimethylsulfonio)propyl]bleomycinamide
N1-(3-(Dimethylsulfonio)propyl)bleomycinamide
NDC 0015-3010
NSC 125066
Pingyangmyvin A2
STOCK1N-74760
UNII-13M89UEA7W
UNII-40S1VHN69B
Zhengguangmycin A2
Zhengguangmycin A2 [Chinese]
bleomycin
bleomycin a2
4
CidofovirapprovedPhase 4, Phase 2, Phase 133113852-37-260613
Synonyms:
(2S)-3-Hydroxy-2-phosphonylmethoxypropyl-cytosine
(S)-(3-(4-amino-2-Oxopyrimidin-1(2H)-yl)-1-hydroxypropan-2-yloxy)methylphosphonic acid
(S)-1-(3-Hydroxy-2-phosphonomethoxypropyl)cytosine
(S)-1-[3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine
(S)-1-[3-Hydroxy-2-(phosphonylmethoxy)propyl]cytosine
(S)-1-[3-hydroxy-2-(phosphonylmethoxy)-propyl]cytosine
(S)-2-(4-Amino-2-oxo-1(2H)-pyrimidinyl-1-(hydroxymethyl)ethoxy)methyl phosphonic acid
(S)-HPMPC
(s)-[[2-(4-amino-2-oxo-1(2h)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic acid
({[(2S)-1-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid
({[(S)-1-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid
1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine
1-(S)-[3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine
1-[(S)-3-Hydroxy-2-(phosphonomethoxy)propyl]-cytosine dihydrate
1-[(S)-3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine
113852-37-2
120362-37-0 (hydrochloride salt)
149394-66-1
AC-1666
AC1L1TLB
AC1Q6C68
AKOS005145721
C8H14N3O6P
CDV
CHEBI:3696
 
CHEMBL152
CID60613
Cidofovir
Cidofovir (Vistide)
Cidofovir (anhydrous)
Cidofovir Anhydrous
Cidofovir anhydrous
Cidofovirum
DB00369
Forvade
GS 0504
GS 504
GS-0504
GS-504
GS504
HPMPC
HSDB 7115
LS-106432
MolPort-005-935-597
NSC742135
S1516_Selleck
UNII-768M1V522C
Vistide
Vistide, Cidofovir
[(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid
[(S)-2-(4-Amino-2-oxo-2H-pyrimidin-1-yl)-1-hydroxymethyl-ethoxymethyl]-phosphonic acid
[[(S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic acid
5
NicotineapprovedPhase 4105054-11-5942, 89594
Synonyms:
(−
(+)-Nicotine
(-)-3-(1-Methyl-2-pyrrolidyl)pyridine
(-)-3-(N-Methylpyrrolidino)pyridine
(-)-Nicotine
(-)-Nicotine solution
(2S) 3-(1-Methyl-pyrrolidin-2-yl)-pyridine
(R)-3-(1-Methyl-2-pyrrolidinyl)pyridine
(R,S)-Nicotine
(S)-(-)-NICOTINE, 3-[(2S)-1-METHYL-2-PYRROLIDINYL] PYRIDINE
(S)-(-)-Nicotine
(S)-(−)-nicotine
(S)-3-(1-methylpyrrolidin-2-yl)pyridine
(S)-3-(N-methylpyrrolidin-2-yl)pyridine
(S)-Nicotine
(−)-nicotine
)-1-Methyl-2-(3-pyridyl)pyrrolidine
)-Nicotine
)-Nicotine solution
1-Methyl-2-(3-pyridal)-Pyrrolidine
1-Methyl-2-(3-pyridal)-pyrrolidene
1-Methyl-2-(3-pyridiyl)pyrrolidine
1-Methyl-2-(3-pyridyl)pyrrolidine
1uw6
2'-beta-H-Nicotine
3-(1-Methyl-2-pyrollidinyl)pyridine
3-(1-Methyl-2-pyrrolidinyl)-Pyridine
3-(1-Methyl-2-pyrrolidinyl)pyridine
3-(1-Methylpyrrolidin-2-yl)pyridine
3-(2-(N-methylpyrrolidinyl))pyridine
3-(N-Methylpyrollidino)pyridine
3-(N-Methylpyrrolidino)pyridine
3-(N-methylpyrollidino)pyridine
3-N-Methylpyrrolidine
3-[(2S)-1-methylpyrrolidin-2-yl]pyridine
36733_FLUKA
36733_RIEDEL
434F7990-3240-4A43-ACEC-E6CC1E495FA0
46343_FLUKA
46343_RIEDEL
54-11-5
AC1L3I79
AC1Q3ZOC
AI3-03424
BB_NC-0777
BIDD:GT0599
BRD-K05395900-322-02-1
Black Leaf
Black Leaf 40
C00745
CCRIS 1637
CHEBI:17688
CHEMBL3
CID89594
CPD000059074
Campbell's Nico-Soap
Caswell No. 597
Commit
D-Nicotine
D03365
DL-tetrahydronicotyrine
Destruxol
Destruxol Orchid Spray
EINECS 200-193-3
ENT 3,424
EPA Pesticide Chemical Code 056702
Emo-Nik
Flux Maag
Fumeto bac
Fumetobac
HSDB 1107
Habitrol
Habitrol (TN)
L(-)-nicotine
L(−)-nicotine
L-3-(1-Methyl-2-pyrrolidyl)pyridine
 
L-Nicotine
LS-202
MLS001055457
MLS001335905
Mach-Nic
Methyl-2-pyrrolidinyl)pyridine
Micotine
MolPort-000-744-731
N3876_SIGMA
N5511_FLUKA
N5511_SIGMA
NCGC00090693-01
NCGC00090693-02
NCGC00090693-03
NCGC00090693-04
NCGC00090693-05
NCGC00090693-06
NCGC00090693-07
NCT
NICOTINE AND SALTS
NSC 5065
NSC97238
Niagara P.A. Dust
Nic-Sal
Nico-Dust
Nico-Fume
Nicocide
Nicoderm
Nicoderm Cq
Nicoderm Patch
Nicorette
Nicorette Plus
Nicotin
Nicotina
Nicotina [Italian]
Nicotine
Nicotine (USP)
Nicotine (compounds related to)
Nicotine Alkaloid
Nicotine Patch
Nicotine Polacrilex
Nicotine [BSI:ISO]
Nicotine [UN1654]
Nicotine [UN1654] [Poison]
Nicotine [USAN]
Nicotrol
Nicotrol Inhaler
Nicotrol Ns
Nictoine patch
Nikotin
Nikotin [German]
Nikotyna
Nikotyna [Polish]
Ortho N-4 Dust
Ortho N-5 Dust
PDSP1_000113
PDSP1_000465
PDSP2_000463
PDSP2_000555
Prostep
R)-(+)-Nicotine
RCRA waste no. P075
RCRA waste number P075
SAM002564224
SDCCGMLS-0066911.P001
SMR000059074
Tendust
Transdermal Nicotine
UN1654
a -N-Methylpyrrolidine
a-N-Methylpyrrolidine
alpha-N-Methylpyrrolidine
beta-Pyridyl-alpha-N-methyl pyrrolidine
beta-Pyridyl-alpha-N-methylpyrrolidine
bmse000105
delta-Nicotine
nicotine
nicotine replacement patch
6
Gabapentinapproved, investigationalPhase 428960142-96-33446
Synonyms:
1-(Aminomethyl)-cyclohexaneacetic acid
1-(Aminomethyl)cyclohexaneacetic acid
2-[1-(aminomethyl)cyclohexyl]acetic acid
60142-96-3
AC-1485
AC1L1FYE
AC1Q53PH
AKOS000280865
Aclonium
Apo-Gabapentin
Apotex brand of gabapentin
Aventis brand of gabapentin
BB_SC-1512
BIDD:GT0656
BPBio1_000993
BRN 2359739
BSPBio_000901
C040029
C9H17NO2
CAS-60142-96-3
CCRIS 7210
CHEBI:188316
CHEBI:42797
CHEMBL940
CI 945
CI-945
CID3446
D00332
DB00996
DDS-2003
DM-1796
DM-5689
EINECS 262-076-3
EU-0100582
G-154
G0318
G154_SIGMA
GBN
GOE 2450
Gabapen
Gabapentin
Gabapentin (JAN/USAN/INN)
Gabapentin GR
Gabapentin Hexal
Gabapentin Stada
Gabapentin [USAN:INN:BAN]
Gabapentin-ratiopharm
Gabapentina
Gabapentine
Gabapentine [INN-French]
Gabapentino
Gabapentino [INN-Spanish]
Gabapentino [Spanish]
Gabapentinum
 
Gabapentinum [INN-Latin]
Gabapetin
Go 3450
Goe-3450
HMS1570N03
HMS2089J03
HSDB 7364
Hexal brand of gabapentin
I06-0677
L000733
LS-7194
Lopac-G-154
Lopac0_000582
MLS000069358
MolPort-000-883-862
NCGC00015466-01
NCGC00015466-02
NCGC00015466-06
NCGC00015466-09
NCGC00016891-01
NCGC00021545-02
NCGC00021545-04
NCGC00021545-05
NSC742194
Neurontin
Neurontin (TN)
Novo-Gabapentin
Novo-Gabapentine
Novopharm brand of gabapentin
PMS-Gabapentin
Parke Davis brand of gabapentin
Pfizer brand of gabapentin
Pharmascience brand of gabapentin
Prestwick0_000861
Prestwick1_000861
Prestwick2_000861
Prestwick3_000861
Prestwick_151
S2133_Selleck
SMR000058311
SPBio_002822
STK598009
Serada
Stadapharm brand of gabapentin
TL8003814
Tocris-0806
UNII-6CW7F3G59X
Vultin
Warner-Lambert brand of gabapentin
[1-(AMINOMETHYL)CYCLOHEXYL]ACETIC ACID
gabapentin
gabapentin (Neurontin)
gabapentina
gabapentinium
ratiopharm brand of gabapentin
7Antiparkinson AgentsPhase 4, Phase 31527
8AnestheticsPhase 4, Phase 3, Phase 19001
9Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 2, Phase 122776
10Anti-Bacterial AgentsPhase 4, Phase 3, Phase 2, Phase 110884
11AnalgesicsPhase 4, Phase 3, Phase 1, Phase 211287
12Antibiotics, AntitubercularPhase 4, Phase 3, Phase 2, Phase 16972
13Neurotransmitter AgentsPhase 4, Phase 3, Phase 2, Phase 117734
14Central Nervous System DepressantsPhase 4, Phase 312806
15Liver ExtractsPhase 4, Phase 3, Phase 2, Phase 13868
16Antiviral AgentsPhase 4, Phase 3, Phase 1, Phase 2, Early Phase 19732
17ExpectorantsPhase 4388
18AntioxidantsPhase 4, Phase 3, Phase 22928
19Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 121402
20AntidotesPhase 4, Phase 3, Phase 21038
21N-monoacetylcystinePhase 4316
22Protective AgentsPhase 4, Phase 3, Phase 1, Phase 27190
23Cholinergic AgentsPhase 4, Phase 3, Phase 23846
24Psychotropic DrugsPhase 4, Phase 3, Phase 2, Phase 16279
25Autonomic AgentsPhase 4, Phase 3, Phase 29774
26Respiratory System AgentsPhase 4, Phase 3, Phase 24818
27Calcium, DietaryPhase 4, Phase 3, Phase 25525
28Nicotinic AgonistsPhase 4902
29Central Nervous System StimulantsPhase 4, Phase 3, Phase 1, Phase 22132
30Excitatory Amino AcidsPhase 41297
31Excitatory Amino Acid AntagonistsPhase 41282
32Tranquilizing AgentsPhase 44164
33
gamma-Aminobutyric AcidPhase 423056-12-2119
Synonyms:
3-Carboxypropylamine
4-Aminobutanoate
4-Aminobutanoic acid
4-Aminobutyrate
4-Aminobutyric acid
Aminalon
GABA
Gaballon
Gamarex
Gammalon
Gammalone
Gammar
Gammasol
 
Mielogen
Mielomade
Omega-Aminobutyrate
Omega-Aminobutyric acid
Piperidate
Piperidic acid
Piperidinate
Piperidinic acid
gamma Aminobutyrate
gamma Aminobutyric acid
gamma-Aminobutyrate
gamma-Aminobutyric acid
w-Aminobutyrate
w-Aminobutyric acid
34GABA AgentsPhase 41622
35Anti-Anxiety AgentsPhase 41816
36AnticonvulsantsPhase 42620
37Antimanic AgentsPhase 4790
38calcium channel blockersPhase 41940
39Omega 3 Fatty AcidNutraceuticalPhase 4, Phase 2969
40arginineNutraceuticalPhase 4, Phase 2, Phase 1408
41
EpirubicinapprovedPhase 3, Phase 2, Phase 138356420-45-241867
Synonyms:
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
(7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione
4'-Epi-DXR
4'-Epiadriamycin
4'-Epidoxorubicin
4'-epi-DX
4'-epi-Doxorubicin
4'-epidoxorubicin
4-Epidoxorubicin
56390-09-1
56390-09-1 (hydrochloride)
56420-45-2
57918-25-9
AC1L26NP
AC1Q6JIV
BRN 1445813
C11230
C27H29NO11
CCRIS 2261
CHEBI:47898
CHEMBL417
CID41867
D07901
DB00445
Ellence
Epi-DX
Epi-Dx
Epiadriamycin
Epidoxorubicin
Epirubicin
 
Epirubicin (INN)
Epirubicin [INN:BAN]
Epirubicina
Epirubicina [INN-Spanish]
Epirubicina [Spanish]
Epirubicine
Epirubicine [French]
Epirubicine [INN-French]
Epirubicinum
Epirubicinum [INN-Latin]
Epirubicinum [Latin]
Farmorubicin (TN)
HSDB 6962
IMI 28
LS-187190
LS-93992
MLS000759412
NChemBio.2007.10-comp15
NSC 256942
NSC-256942
NSC256942
Pharmorubicin Pfs
Pidorubicin
Pidorubicina
Pidorubicina [INN-Spanish]
Pidorubicine
Pidorubicine [INN-French]
Pidorubicinum
Pidorubicinum [INN-Latin]
Ridorubicin
SMR000466308
Triferric doxorubicin
UNII-3Z8479ZZ5X
WP 697
42
Sevofluraneapproved, vet_approvedPhase 347928523-86-65206
Synonyms:
1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane
28523-86-6
AC-15484
AC1L1JU0
BRN 2041023
Bax 3084
C009250
C07520
C4H3F7O
CHEBI:9130
CHEMBL1200694
CID5206
D00547
DB01236
F0691
Fluoromethyl 1,1,1,3,3,3-Hexafluoroisopropyl Ether
Fluoromethyl 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether
I14-13357
LS-67851
MR6S4
 
MR_6S4
MolPort-001-775-746
NCGC00167421-01
PC4681
Sevofluran
Sevoflurane
Sevoflurane (JAN/USAN/INN)
Sevoflurane [USAN:INN:BAN:JAN]
Sevoflurano
Sevoflurano [INN-Spanish]
Sevofluranum
Sevofluranum [INN-Latin]
Sevofrane
Sevorane
Sojourn
UNII-38LVP0K73A
Ultane
Ultane (TN)
ZINC01530810
fluoromethyl hexafluoroisopropyl ether
fluoromethyl-2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether
sevoflurane
43TegafurapprovedPhase 3, Phase 29017902-23-7
44
CitalopramapprovedPhase 350359729-33-82771
Synonyms:
1,3-Dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-5-isobenzofurancarbonitrile
1,3-dihydro[3,4]benzofuran-5-carbonitrile
1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile
59729-33-8
AB00513896
AC-12214
AC1L1EFH
AE-641/00603021
Akarin
BPBio1_000929
BRD-A47598013-004-02-0
BSPBio_000843
Bonitrile
C07572
C20H21FN2O
CHEBI:3723
CHEMBL549
CID2771
CPD000465669
Celapram
Celexa
Celius
Ciazil
Cilift
Cipram
Cipramil
Ciprapine
Citabax
Citadur
Citadur (TN)
Citalec
Citalopram (USP/INN)
Citalopram Hydrobromide
Citalopram [Celexa]
Citalopram [INN:BAN]
Citalopram hydrobromide
Citalopramum
Citalopramum [INN-Latin]
 
Citol
Citopam
Citox
Citrol
Cytalopram
D07704
DB00215
Dalsan
EINECS 261-891-1
Elopram
HMS2090O09
HMS2093A14
Humorup
I01-0382
InChI=1/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3
L001223
LS-84327
Lopac0_000258
Lu 10-171
Lu-10-171
MolPort-003-666-794
NCGC00015267-07
NCGC00025160-02
Nitalapram
Oropram
Pramcit
Prestwick3_000692
Recital
SAM002589960
ST069372
STL058639
Seropram
Talam
Talohexal
Temperax
UNII-0DHU5B8D6V
Vodelax
Zentius
Zetalo
[3H]Citalopram
citalopram
45
CarboplatinapprovedPhase 3, Phase 2, Phase 1198041575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
46
Epinephrineapproved, vet_approvedPhase 3, Phase 293351-43-45816
Synonyms:
(-)-(R)-Epinephrine
(-)-3,4-Dihydroxy-a-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-alpha-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-dihydroxy-a-[(methylamino)methyl]-Benzyl alcohol
(-)-3,4-dihydroxy-alpha-[(methylamino)methyl]-Benzyl alcohol
(-)-Adrenalin
(-)-Adrenaline
(-)-Epinephrine
(-)-R-Epinephrine
(R)-(-)-Adnephrine
(R)-(-)-Adrenaline
(R)-(-)-Epinephrine
(R)-(-)-Epirenamine
(R)-(−)-adrenaline
(R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
(R)-4-[1-hydroxy-2-(methylamino)ethyl]-1,2-Benzenediol
(R)-Adrenaline
(R)-Epinephrine
(−)-adrenaline
02252_FLUKA
1-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
1-Adrenalin
1-Epinephrine
4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol
4-(1-hydroxy-2-methylamino-ethyl)benzene-1,2-diol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-Benzenediol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol
51-43-4
51-43-4 (FREE BASE)
51028-73-0
A0173
AC-13188
AC1L1L7B
ADR ADRENALINE
ADROP
AI3-19015
Adnephrine
Adrenal
Adrenalin
Adrenalin (TN)
Adrenalin in Oil
Adrenalin-Medihaler
Adrenalina
Adrenalina [DCIT]
Adrenaline
Adrenaline (JP15)
Adrenaline/Epinephrine
Adrenalinum
Adrenamine
Adrenan
Adrenapax
Adrenasol
Adrenatrate
Adrenine
Adrenodis
Adrenohorma
Adrenosan
Adrenutol
Adrin
Adrine
Ana-Guard
Ana-Kit
Antiasthmatique
Asmatane Mist
Asthma meter mist
Asthma-nefrin
Asthmahaler Mist
Asthmanefrin
Astmahalin
Astminhal
BIDD:GT0119
Balmadren
Bernarenin
Biorenine
Bosmin
Brevirenin
Bronkaid
Bronkaid Mist
Bronkaid Suspension Mist
Bupivacaine Hcl and Epinephrine
C00788
CCRIS 4812
CHEBI:28918
CHEMBL679
CID5816
Chelafrin
Citanest Forte
Corisol
D-Epifrin
D-Epinephrine
D00095
DB00668
Drenamist
Dylephrin
Dyspne-Inhal
E4250_SIGMA
EINECS 200-098-7
EPI E Z PEN JR
EPIPEN E Z PEN
EPIPEN JR
Epi EZ Pen Jr
Epifrin
Epiglaufrin
Epinefrin
Epinefrin [Czech]
Epinefrina
Epinefrina [INN-Spanish]
Epinephran
Epinephrin
Epinephrine
Epinephrine (USP)
Epinephrine (USP/INN)
Epinephrine [USAN:INN:JAN]
Epinephrine hydrochloride
Epinephrinum
Epinephrinum [INN-Latin]
Epipen
Epipen (TN)
Epipen Auto-Injector
Epipen EZ Pen
Epipen Jr.
Epipen Jr. Auto-Injector
Epirenamine
Epirenan
Epirenin
Epitrate
Eppy
Esphygmogenina
Exadrin
 
Glaucon
Glaucosan
Glauposine
Glycirenan
HSCI1_000215
HSDB 4289
Haemostasin
Haemostatin
Hektalin
Hemisine
Hemostasin
Hemostatin
Hypernephrin
Hyporenin
IOP
Intranefrin
Iontocaine
Isoptoepinal
Kidoline
L-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
L-Adrenaline
L-Adrenaline Base
L-Epinehphrine
L-Epinephrine
L-Epirenamine
L-Methylaminoethanolcatechol
L-epinephrine
LS-156
Levo-Methylaminoethanolcatechol
Levoadrenaline
Levoepinephrine
Levorenen
Levorenin
Levorenine
Levoreninum
Lopac-E-4642
Lyodrin
Lyophrin
Medihaler-Epi
Metanephrin
Methylaminoethanolcatechol
Methylarterenol
Micronefrin
Micronephrine
MolPort-002-051-368
Mucidrina
Myosthenine
Mytrate
NCGC00015417-01
NCGC00142615-01
NCGC00142615-03
NCGC00142615-04
NCGC00142615-05
NCGC00142615-06
NCGC00142615-07
NSC 62786
NSC62786
Nephridine
Nieraline
PDSP1_001120
PDSP2_001104
Paranephrin
Primatene
Primatene Mist
R-(-)-Epinephrine
R-Adrenaline
RCRA waste no. P042
Racemic Epinephrine
Racepinephrine
Rcra waste number P042
Renagladin
Renaglandin
Renaglandulin
Renaleptine
Renalina
Renoform
Renostypricin
Renostypticin
Renostyptin
SMP1_000227
ST069368
SUS-PHRINE SULFITE-FREE
Scurenaline
Septocaine
Simplene
Sindrenina
Soladren
Sphygmogenin
Stryptirenal
Styptirenal
Supracapsulin
Supradin
Supranefran
Supranephrane
Supranephrine
Supranol
Suprarenaline
Suprarenin
Suprel
Surenine
Surrenine
Sus-Phrine
Sus-phrine
Susphrine
Sympathin I
Takamina
Takamine
Tokamina
Tonogen
Twinject
Twinject 0.15
Twinject 0.3
Twinject 0.30
UNII-YKH834O4BH
Vaponefrin
Vasoconstrictine
Vasoconstrictor
Vasodrine
Vasoton
Vasotonin
adrenaline
bmse000316
d-Adrenaline
epinephrine
l-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
l-Adrenalin
l-Adrenaline
l-Epinephine
l-Epinephrine (synthetic)
l-Epirenamine
l-Methylaminoethanolcatechol
levoepinephrine
nchembio747-comp9
47
Paclitaxelapproved, vet_approvedPhase 3, Phase 1, Phase 2275833069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nab-paclitaxel
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
48
BenzocaineapprovedPhase 318921994-09-7, 94-09-72337
Synonyms:
(p-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
4-amino-benzoic acid ethyl ester
4-aminobenzoic acid ethyl ester
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
AE-562/40377256
AI3-02081
AKOS000119763
AR-1H9065
Acetate, Benzocaine
Aethoform
Aethylium paraminobenzoicum
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthone
BB_SC-0019
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
Baby Anbesol
Bensokain
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
Benzocaine
Benzocaine (USP/INN)
Benzocaine Acetate
Benzocaine Formate
Benzocaine Hydrobromide
Benzocaine Hydrochloride
Benzocaine Methanesulfonate
Benzocaine [INN:BAN]
Benzocainum
Benzocainum [INN-Latin]
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
C07527
CAS-94-09-7
CHEBI:116735
CHEMBL278172
CID2337
Caswell No. 430A
Chloraseptic
D001566
D00552
DB01086
Dermoplast
Diet Ayds
DivK1c_000932
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
ETHYL-P-AMINOBENZOATE
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
Ethyl 4-aminobenzoic acid
Ethyl Aminobenzoate
Ethyl PABA
 
Ethyl aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
Ethyl aminobenzoic acid
Ethyl p-Aminobenzoate
Ethyl p-Aminophenylcarboxylate
Ethyl p-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
Formate, Benzocaine
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Hurricaine
Hydrobromide, Benzocaine
Hydrochloride, Benzocaine
I05-0204
IDI1_000932
Identhesin
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Keloform
LS-35847
MLS001331704
MLS002153970
Methanesulfonate, Benzocaine
MolPort-000-871-526
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
NINDS_000932
NSC 122792
NSC 41531
NSC41531
NSC4688
Norcain
Norcaine
Norcainum
Oprea1_750694
Oprea1_827402
Ora-jel
Orabase-B
Orthesin
Otocain
Outgro
Parathesin
Parathesin (TN)
Parathesine
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Prestwick_991
SMR000059025
SPBio_000134
SPBio_002844
SPECTRUM1500139
STK043620
Slim Mint Gum
Solarcaine
Solu H
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
Spectrum_000074
Topcaine
UNII-U3RSY48JW5
WLN: ZR DVO2
ZINC12358719
benzocaine
ethylaminobenzoate-4
h-4-abz-oet
nchembio.182-comp4
p-(Ethoxycarbonyl)aniline
p-Aminobenzoate
p-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
p-Carbethoxyaniline
p-Ethoxycarboxylic Aniline
p-Ethoxycarboxylic aniline
49
Fentanylapproved, illicit, investigational, vet_approvedPhase 3773437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
1-phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl CII
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
Fentanyl-12
Fentanyl-25
 
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidyl)propionanilide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenethyl-4-(N-propionylanilino)piperidine
N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
UNII-UF599785JZ
fentanyl
50
Propofolapproved, investigational, vet_approvedPhase 310282078-54-84943
Synonyms:
2, 6-Diisopropylphenol
2,6 Diisopropylphenol
2,6-Bis(1-methylethyl)phenol
2,6-Bis(Isopropyl)-phenol
2,6-DIISOPROPYLPHENOL
2,6-Diisopropyl phenol
2,6-Diisopropylphenol
2,6-bis(1-methylethyl)-phenol
2,6-di(propan-2-yl)phenol
2078-54-8
28449-97-0
4-06-00-03435 (Beilstein Handbook Reference)
50356-15-5
AB00513968
AC-2038
AC1L1J9Y
AC1Q1OUI
AI3-26295
AM-149
Abbott Brand of Propofol
Alpha Brand of Propofol
Ampofol
Aquafol
Astra Brand of Propofol
AstraZeneca Brand of Propofol
BIDD:GT0436
BPBio1_000950
BPBio1_000969
BRD-K82255054-001-03-5
BRN 1866484
BSPBio_000862
Biomol-NT_000248
Braun Brand of Propofol
C07523
C12H18O
CAS-2078-54-8
CCRIS 9000
CHEBI:44915
CHEMBL526
CID4943
CPD-11437
CPD000059151
Curamed Brand of Propofol
D00549
D015742
D0617
D126608
D126608_ALDRICH
DB00818
DDS-04F
Diisopropylphenol
Dipravan
Diprivan
Diprivan (TN)
Diprivan Injectable emulsion
Disoprivan
Disoprofol
EINECS 218-206-6
EU-0100437
Fresenius Brand of Propofol
Fresenius Kabi Brand of Propofol
Fresofol
HMS1570L04
HMS2089O21
HMS2094E17
 
HSDB 7123
ICI 35,868
ICI 35868
ICI-35,868
ICI-35868
ICI35,868
ICI35868
InChI=1/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H
Ivofol
Jsp004266
Juste Brand of Propofol
LS-996
Lopac-D126608
Lopac0_000437
MLS001066348
MLS001335999
MLS002454360
MolPort-001-794-517
NCGC00015389-01
NCGC00015389-02
NCGC00015389-04
NCGC00015389-09
NCGC00091538-01
NCGC00091538-02
NCGC00091538-03
NCGC00091538-04
NCGC00091538-05
NCGC00091538-06
NSC 5105
NSC5105
PFL
Parnell Brand of Propofol
Pisa Brand of Propofol
Prestwick0_000931
Prestwick1_000931
Prestwick2_000931
Prestwick3_000931
Propofol
Propofol (JAN/USAN/INN)
Propofol Abbott
Propofol Fresenius
Propofol IDD-D
Propofol MCT
Propofol Rovi
Propofol [USAN:INN:BAN]
Propofol(2,6-Diisopropylphenol)
Propofol-Lipuro
Propofolum
Propofolum [Latin]
Rapinovet
Recofol
Rovi Brand of Propofol
S01-0189
SAM002264610
SMR000059151
SPBio_003031
SPECTRUM1505022
ST50405911
Schering Brand of Propofol
UNII-YI7VU623SF
W505102_ALDRICH
ZD-0859
ZINC00968303
Zeneca Brand of Propofol
ghl.PD_Mitscher_leg0.558
nchembio.552-comp7
propofol

Interventional clinical trials:

(show top 50)    (show all 551)
idNameStatusNCT IDPhase
1THE USE OF N-ACETYLCYSTEINE ATTENUATING CISPLATIN-INDUCED TOXICITIES BY OXIDATIVE STRESSUnknown statusNCT02241876Phase 4
2Clasic Laryngeal Mask Airway(C-LMA) and I-gel Releated Regurgitation and ComplicationsUnknown statusNCT01876836Phase 4
3Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit SmokingCompletedNCT00365508Phase 4
4Comparison of Laryngeal Mask Airway (LMA®) and Tracheal Tube in Modified Radical Mastectomy on Breast CancerCompletedNCT00638599Phase 4
5Comparison of Two Immunomodulatory Formulas on the Number of Postoperative Infections in Head & Neck Cancer PatientsCompletedNCT02622880Phase 4
6Study Using the Medpulser Electroporation System With Bleomycin to Treat Head and Neck CancerCompletedNCT00198263Phase 4
7Use of Cidofovir for Recurrent Respiratory PapillomatosisCompletedNCT00205374Phase 4
8Effect of Gabapentin on Postoperative Pain Control Among Head and Neck Cancer PatientsRecruitingNCT02926573Phase 4
9the Comparison of Voice Quality in Early Laryngeal Cancer Between Surgery and RadiotherapyUnknown statusNCT00497588Phase 3
10Evaluation of 3DCRT Versus IGRT and Analysis of Early Response in Head and Neck Cancer.Unknown statusNCT01124409Phase 3
11Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)Unknown statusNCT00117572Phase 3
12PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck CancerUnknown statusNCT00720070Phase 3
13Biomarkers in Patients With Metastatic or Recurrent Head and Neck Cancer Treated With Cisplatin and Cetuximab on ECOG-E5397Unknown statusNCT01466244Phase 3
14S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck CancerUnknown statusNCT00336947Phase 3
15Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck CancerUnknown statusNCT00002659Phase 3
16Comparing Local Anesthesia With General Anesthesia for Breast Cancer SurgeryUnknown statusNCT00938171Phase 3
17Double-blind, Placebo-controlled, Randomized Study of the Effectiveness of Escitalopram on Emotional Distress of Head and Neck Cancer Patients During Cancer TreatmentUnknown statusNCT00935675Phase 3
18Concomitant Tracheostomy and Lung ResectionUnknown statusNCT01053624Phase 3
19Randomized Trial of ARCON in Larynx CancerCompletedNCT00147732Phase 3
20Patient Selection for Hypoxia Modifying Treatments in Larynx CarcinomasCompletedNCT00160095Phase 3
21Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Cancer of the LarynxCompletedNCT00002496Phase 3
22Comparison of 2 Cefazolin Prophylactic Protocol in Laryngectomy PatientsCompletedNCT00467948Phase 3
23Radiation Therapy in Treating Patients With Stage II Cancer of the Vocal CordCompletedNCT00002727Phase 3
24Combination Chemotherapy Plus Radiation Therapy To Preserve the Larynx in Patients With Cancer of the Hypopharynx or LarynxCompletedNCT00002839Phase 3
25Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or LarynxCompletedNCT00004234Phase 3
26Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck CancerCompletedNCT00090337Phase 3
27Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck CancerCompletedNCT00002533Phase 2, Phase 3
28Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
29Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck CancerCompletedNCT00017511Phase 3
30Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck CancerCompletedNCT00006799Phase 3
31Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck CancerCompletedNCT00002476Phase 3
32Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive TractCompletedNCT00765440Phase 3
33Fruit and Vegetable Extracts in Treating Patients With Stage I-IV, Stage IVA/IVB Head and Neck CancerCompletedNCT00064298Phase 3
34Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck CancerCompletedNCT00002507Phase 3
35Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck CancerCompletedNCT00656513Phase 2, Phase 3
36Radiation Therapy in Treating Patients With Head and Neck CancerCompletedNCT00021125Phase 3
37Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck CancerCompletedNCT00004917Phase 3
38Combination Chemotherapy in Treating Patients With Advanced Head and Neck CancerCompletedNCT00002888Phase 3
39Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck CancerCompletedNCT00003809Phase 3
40Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During SurgeryCompletedNCT00002670Phase 3
41Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck CancerCompletedNCT00008398Phase 3
42Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)CompletedNCT00095875Phase 3
43Radiation Therapy Cisplatin With or Without Fluorouracil Patients With Stage III or Stage IV Head and Neck CancerCompletedNCT00608205Phase 3
44Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck CancerCompletedNCT00003592Phase 3
45Surgery and Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer That Can Be Removed During SurgeryCompletedNCT00003576Phase 3
46Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck CancerCompletedNCT00054561Phase 3
47Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Head and Neck CancerCompletedNCT00002654Phase 3
48Radiation Therapy Plus Porfiromycin in Treating Patients With Stage III or Stage IV Head and Neck CancerCompletedNCT00003328Phase 3
49Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck CancerCompletedNCT00006481Phase 3
50High-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck CancerCompletedNCT00002555Phase 3

Search NIH Clinical Center for Larynx Cancer


Cochrane evidence based reviews: laryngeal neoplasms

Genetic Tests for Larynx Cancer

About this section

Genetic tests related to Larynx Cancer:

id Genetic test Affiliating Genes
1 Laryngeal Carcinoma26

Anatomical Context for Larynx Cancer

About this section

MalaCards organs/tissues related to Larynx Cancer:

35
Lung, Breast, Skin, Lymph node, Thyroid, Liver, Brain

FMA organs/tissues related to Larynx Cancer:

17
The larynx

Animal Models for Larynx Cancer or affiliated genes

About this section

MGI Mouse Phenotypes related to Larynx Cancer:

40 (show all 16)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053918.5CCND1, CD44, CDKN2A, CTSD, EGFR, MMP2
2MP:00053798.3CCND1, CD44, CDKN2A, CTSD, EGFR, NME1
3MP:00053888.3CCND1, CD44, CDKN2A, EGFR, MMP2, PDPN
4MP:00028738.0CCND1, CD44, EGFR, MKI67, MMP2, PTEN
5MP:00053907.9CCND1, CD44, CDKN2A, EGFR, MMP2, PDPN
6MP:00036317.3CCND1, CD44, CDKN2A, CTSD, EGFR, MMP2
7MP:00020067.1CCND1, CD44, CDKN2A, EGFR, FHIT, GSTP1
8MP:00107717.1CCND1, CD44, CDKN2A, CTSD, EGFR, FHIT
9MP:00053817.0CCND1, CD44, CDKN2A, CTSD, EGFR, FHIT
10MP:00053877.0CCND1, CD44, CDKN2A, CTSD, EGFR, FHIT
11MP:00053856.9CCND1, CD44, CDKN2A, CTSD, EGFR, HSP90AB1
12MP:00053976.9CCND1, CD44, CDKN2A, CTSD, EGFR, FHIT
13MP:00053786.5CCND1, CD44, CDKN2A, CTSD, EGFR, GSTP1
14MP:00053766.0CCND1, CD44, CDKN2A, CTSD, EGFR, FHIT
15MP:00107685.9CCND1, CD44, CDKN2A, CTSD, EGFR, FHIT

Publications for Larynx Cancer

About this section

Articles related to Larynx Cancer:

(show top 50)    (show all 52)
idTitleAuthorsYear
1
An update on larynx cancer. (27898173)
2017
2
Tumor volume as a prognostic factor for local control and overall survival in advanced larynx cancer. (26333005)
2016
3
Functional Organ Preservation in Larynx Cancer: A Continuing Debate. (27511720)
2016
4
Identification of microRNA profile specific to cancer stem-like cells directly isolated from human larynx cancer specimens. (27816053)
2016
5
A comparison of overall survival for patients with T4 larynx cancer treated with surgical versus organ-preservation approaches: A National Cancer Data Base analysis. (27727461)
2016
6
Carotid blowout syndrome in patients treated by larynx cancer. (27789194)
2016
7
Could the Addition of Cetuximab to Conventional Radiation Therapy Improve Organ Preservation in Those Patients With Locally Advanced Larynx Cancer Who Respond to Induction Chemotherapy? An Organ Preservation Spanish Head and Neck Cancer Cooperative Group Phase 2 Study. (28011050)
2016
8
Effect of airway dynamics on the development of larynx cancer. (26372301)
2016
9
Severe late dysphagia and cause of death after concurrent chemoradiation for larynx cancer in patients eligible for RTOG 91-11. (27208840)
2016
10
Classification of TP53 mutations and HPV predict survival in advanced larynx cancer. (27345657)
2016
11
The matrix metalloproteinase in larynx cancer. (28026822)
2016
12
Relation between Endothelial Nitric Oxide Synthase Genotypes and Oxidative Stress Markers in Larynx Cancer. (26682008)
2016
13
Functional state of the Hsp27 chaperone as a molecular marker of an unfavorable course of larynx cancer. (27540972)
2016
14
A Multidisciplinary Approach to Larynx Cancer: One Size Does Not Fit All. (27511719)
2016
15
Inter- and Intrafraction Target Motion in Highly Focused Single Vocal Cord Irradiation of T1a Larynx Cancer Patients. (26094125)
2015
16
Occupational polycyclic aromatic hydrocarbon exposure and risk of larynx cancer: a systematic review and meta-analysis. (25398415)
2015
17
Association of Polymorphic Variants of miRNA Processing Genes with Larynx Cancer Risk in a Polish Population. (26688807)
2015
18
MiR-221 as a pre- and postoperative plasma biomarker for larynx cancer patients. (25945817)
2015
19
Total Laryngectomy Versus Larynx Preservation for T4a Larynx Cancer: Patterns of Care and Survival Outcomes. (26068492)
2015
20
Sparing surgery with the use of TiNi-based endografts in larynx cancer patients. (25176032)
2015
21
Organ Preservation for Advanced Larynx Cancer: Issues and Outcomes. (26351339)
2015
22
Biomarkers in advanced larynx cancer. (23775802)
2014
23
Transoral robotic surgery for larynx cancer. (24882796)
2014
24
Changing paradigms in treatment of larynx cancer. (24830964)
2014
25
Five-year relative survival rate of larynx cancer in the USA, Europe and Japan. (25274601)
2014
26
Association of C722T polymorphism in XRCC3 gene with larynx cancer: a meta-analysis. (24523020)
2014
27
Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. (23182993)
2013
28
Chemoselection: a paradigm for optimization of organ preservation in locally advanced larynx cancer. (24053204)
2013
29
Mycobiota of the air in hospital rooms and the fungal colonisation of tracheostomy tubes used by patients diagnosed with larynx cancer--preliminary research. (24171299)
2013
30
The nicotine dependence phenotype, time to first cigarette, and larynx cancer risk. (22367700)
2012
31
Correlation between expression of cellular retinol-binding protein 1 and its methylation status in larynx cancer. (22049223)
2012
32
Polymorphisms of the DNA repair genes XRCC1 and ERCC4 are not associated with smoking- and drinking-dependent larynx cancer in a Polish population. (21423097)
2011
33
CD44 expression predicts local recurrence after radiotherapy in larynx cancer. (20837694)
2010
34
The Cys326 allele of the 8-oxoguanine DNA N-glycosylase 1 gene as a risk factor in smoking- and drinking-associated larynx cancer. (19966524)
2009
35
Hexosaminidase as a new potential marker for larynx cancer. (19298806)
2009
36
Increased risk of larynx cancer in heterozygous carriers of the I171V mutation of the NBS1 gene. (17894553)
2007
37
Annexin 1: differential expression in tumor and mast cells in human larynx cancer. (17340616)
2007
38
Lack of prognostic significance of carcinoembryonic antigen (CEA) preoperative serum levels in patients with advanced larynx cancer]. (16969905)
2006
39
Inmunohistochimic expresion of p53 protein and TTS prognostic value in the larynx cancer]. (15663083)
2004
40
Reduced expression of connexin 31.1 in larynx cancer is not caused by GJB5 mutations. (15363549)
2004
41
Correlation among loss of heterozygosity, promoter methylation and protein expression of MLH1 in larynx cancer. (14767526)
2004
42
Polymorphisms of arylamine N-acetyltransferase (NAT1 and NAT2) and larynx cancer susceptibility. (12037388)
2002
43
High-activity microsomal epoxide hydrolase genotypes and the risk of oral, pharynx, and larynx cancers. (10676631)
2000
44
Influence of glutathione S-transferase M1 and T1 genotypes on larynx cancer risk among Korean smokers. (11097350)
2000
45
Correlation of p53 and the proto-oncogene eIF4E in larynx cancers: prognostic implications. (10910074)
2000
46
Glutathione S-transferase GSTM3 and GSTP1 genotypes and larynx cancer risk. (10067818)
1999
47
Larynx cancer risk in relation to glutathione S-transferase M1 and T1 genotypes and tobacco smoking. (9456238)
1998
48
nm23 Protein expression in larynx cancer and the relationship with metastasis. (9616278)
1997
49
Correlation between the clinical stage of larynx cancer in male and female and levels of steroid hormones in serum]. (9045129)
1996
50
Heterologous epidermal growth factor receptor (EGF-R) expression in larynx cancer cell lines: evidence for the existence of structurally modified receptors. (8291440)
1993

Variations for Larynx Cancer

About this section

Cosmic variations for Larynx Cancer:

8 (show top 50)    (show all 145)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM13223CDKN2Aupper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.151-1G>Ap.?13
2COSM13299CDKN2Aupper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.250G>Tp.D84Y13
3COSM44103TP53upper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.737T>Ap.M246K13
4COSM5072PTENupper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.615G>Ap.M205I13
5COSM13780CDKN2Aupper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.290T>Cp.L97P13
6COSM10750TP53upper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.490A>Tp.K164*13
7COSM44735TP53upper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.825T>Cp.C275C13
8COSM4387392CDKN2Aupper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.269T>Cp.F90S13
9COSM44388TP53upper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.853G>Tp.E285*13
10COSM43650TP53upper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.638G>Tp.R213L13
11COSM10659TP53upper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.817C>Tp.R273C13
12COSM6549TP53upper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.743G>Tp.R248L13
13COSM43597TP53upper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.538G>Tp.E180*13
14COSM10687TP53upper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.527G>Ap.C176Y13
15COSM45544TP53upper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.947C>Tp.P316L13
16COSM10704TP53upper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.844C>Tp.R282W13
17COSM11354TP53upper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.991C>Tp.Q331*13
18COSM10660TP53upper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.818G>Ap.R273H13
19COSM484HRASupper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.35G>Ap.G12D13
20COSM45580TP53upper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.765C>Tp.I255I13
21COSM43941TP53upper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.400T>Gp.F134V13
22COSM44306TP53upper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.845G>Cp.R282P13
23COSM44071TP53upper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.955A>Gp.K319E13
24COSM45685TP53upper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.613T>Ap.Y205N13
25COSM5093PTENupper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.992A>Gp.D331G13
26COSM43842TP53upper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.770T>Cp.L257P13
27COSM5273PTENupper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.362C>Ap.A121E13
28COSM26129EGFRupper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.2572C>Tp.L858L13
29COSM43826TP53upper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.706T>Ap.Y236N13
30COSM43753TP53upper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.560-1G>Ap.?13
31COSM44459TP53upper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.777C>Ap.D259E13
32COSM1238071EGFRupper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.2113A>Gp.R705G13
33COSM44345TP53upper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.915G>Tp.K305N13
34COSM10656TP53upper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.742C>Tp.R248W13
35COSM43836TP53upper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.475G>Cp.A159P13
36COSM11305TP53upper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.809T>Cp.F270S13
37COSM563NRASupper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.34G>Ap.G12S13
38COSM43949TP53upper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.401T>Gp.F134C13
39COSM760PIK3CAupper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.1624G>Ap.E542K13
40COSM11564TP53upper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.742C>Gp.R248G13
41COSM11658TP53upper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.955A>Tp.K319*13
42COSM13546CDKN2Aupper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.221A>Tp.D74V13
43COSM10647TP53upper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.404G>Tp.C135F13
44COSM13830CDKN2Aupper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.341C>Ap.P114H13
45COSM10810TP53upper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.725G>Tp.C242F13
46COSM13828CDKN2Aupper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.149A>Gp.Q50R13
47COSM10988TP53upper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.772G>Ap.E258K13
48COSM45571TP53upper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.593A>Gp.E198G13
49COSM43555TP53upper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.736A>Gp.M246V13
50COSM6815TP53upper aerodigestive tract,larynx,carcinoma,squamous cell carcinomac.461G>Tp.G154V13

Expression for genes affiliated with Larynx Cancer

About this section
Search GEO for disease gene expression data for Larynx Cancer.

Pathways for genes affiliated with Larynx Cancer

About this section

Pathways related to Larynx Cancer according to GeneCards Suite gene sharing:

(show all 34)
idSuper pathwaysScoreTop Affiliating Genes
1
Show member pathways
9.8GSTM1, GSTP1, GSTT1
29.8GSTM1, GSTP1, GSTT1
39.8GSTM1, GSTP1, GSTT1
49.8NME1, TERT, TP53
5
Show member pathways
9.8GSTM1, GSTP1, NAT2
69.7CCND1, MMP2, TERT
7
Show member pathways
9.6GSTM1, GSTM3, GSTP1, GSTT1
89.6CD44, EGFR, MMP2
99.6CCND1, MMP2, XRCC1
109.5EGFR, PTEN, TP53
119.5CD44, CDKN2A, PTEN, TP53
129.4CCND1, CDKN2A, TERT, TP53
139.4CCND1, EGFR, TERT
149.4CCND1, EGFR, PTEN
159.3CCND1, EGFR, MMP2, TP53
16
Show member pathways
9.3CCND1, CDKN2A, EGFR, TP53
17
Show member pathways
9.3CCND1, HSP90AB1, PTEN, TP53
18
Show member pathways
9.2CCND1, EGFR, PTEN, TP53
199.2CCND1, EGFR, PTEN, TP53
20
Show member pathways
9.2CCND1, EGFR, PTEN, TP53
21
Show member pathways
9.2CCND1, EGFR, MMP2, PTEN
229.1CCND1, FHIT, PTEN, TP53
23
Show member pathways
9.1CCND1, CDKN2A, CTSD, PTEN, TP53
249.1CCND1, CD44, EGFR, MMP2, TP53
259.1CCND1, CDKN2A, EGFR, MMP2, TP53
269.0CTSD, EGFR, MMP2, PTEN, TP53
279.0CCND1, CDKN2A, EGFR, PTEN, TP53
288.8CCND1, EGFR, HSP90AB1, PTEN, TP53
298.8CCND1, CDKN2A, GSTP1, MKI67, TP53, XRCC1
30
Show member pathways
8.8CCND1, EGFR, HSP90AB1, MMP2, PTEN
318.7CCND1, CD44, CDKN2A, EGFR, PTEN, TP53
328.6CCND1, EGFR, HSP90AB1, NME1, PTEN, TP53
338.0CCND1, CDKN2A, EGFR, GSTP1, HSP90AB1, MMP2
34
Show member pathways
7.8CCND1, CDKN2A, EGFR, FHIT, GSTP1, HSP90AB1

GO Terms for genes affiliated with Larynx Cancer

About this section

Cellular components related to Larynx Cancer according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1cytosolGO:00058297.2CCND1, CDKN2A, FHIT, GSTM1, GSTM3, GSTP1
2cytoplasmGO:00057376.2CCND1, CD44, CDKN2A, EGFR, FHIT, GSTM1

Biological processes related to Larynx Cancer according to GeneCards Suite gene sharing:

(show all 19)
idNameGO IDScoreTop Affiliating Genes
1cellular detoxification of nitrogen compoundGO:007045810.8GSTM1, GSTM3
2nitrobenzene metabolic processGO:001891610.8GSTM1, GSTM3
3xenobiotic catabolic processGO:004217810.6GSTM1, GSTM3
4mitotic G1 DNA damage checkpointGO:003157110.5CCND1, TP53
5purine nucleotide metabolic processGO:000616310.5FHIT, NME1
6response to UV-AGO:007014110.3CCND1, EGFR
7glutathione derivative biosynthetic processGO:190168710.3GSTM1, GSTM3, GSTP1, GSTT1
8positive regulation of vascular smooth muscle cell proliferationGO:190470710.3MMP2, TERT
9positive regulation of superoxide anion generationGO:003293010.2EGFR, GSTP1
10replicative senescenceGO:009039910.2CDKN2A, TERT, TP53
11animal organ regenerationGO:003110010.1CCND1, GSTP1, MKI67
12glutathione metabolic processGO:00067499.9GSTM1, GSTM3, GSTP1, GSTT1
13response to organic cyclic compoundGO:00140709.6CCND1, EGFR, MKI67, PTEN
14cellular response to drugGO:00356909.5EGFR, HSP90AB1, NME1, TP53
15response to organic substanceGO:00100339.4CCND1, HSP90AB1, PTEN, XRCC1
16response to estradiolGO:00323559.3CCND1, EGFR, GSTP1, PTEN
17response to drugGO:00424938.9CCND1, HSP90AB1, NME1, PTEN, XRCC1
18cell proliferationGO:00082838.5EGFR, MKI67, PDPN, PTEN, TP53
19negative regulation of apoptotic processGO:00430668.5CD44, EGFR, GSTP1, HSP90AB1, PTEN, TERT

Molecular functions related to Larynx Cancer according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1glutathione bindingGO:004329510.5GSTM1, GSTM3, GSTP1
2nitric-oxide synthase regulator activityGO:003023510.2EGFR, HSP90AB1
3glutathione transferase activityGO:000436410.2GSTM1, GSTM3, GSTP1, GSTT1
4identical protein bindingGO:00428028.6EGFR, FHIT, GSTM3, NME1, PTEN, TP53
5enzyme bindingGO:00198998.2CCND1, EGFR, GSTM1, GSTM3, NME1, PTEN
6protein kinase bindingGO:00199018.2CCND1, CDKN2A, EGFR, GSTP1, HSP90AB1, NME1

Sources for Larynx Cancer

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
26GTR
27HGMD
28HMDB
29ICD10
30ICD10 via Orphanet
31ICD9CM
32IUPHAR
33KEGG
36MedGen
38MeSH
39MESH via Orphanet
40MGI
43NCI
44NCIt
45NDF-RT
48NINDS
49Novoseek
51OMIM
52OMIM via Orphanet
56PubMed
57QIAGEN
62SNOMED-CT via Orphanet
66Tumor Gene Family of Databases
67UMLS
68UMLS via Orphanet